Press release

LUMICKS enters collaboration with LAVA Therapeutics to characterize its tumor-specific γδ T-cell engagers

Amsterdam, the Netherlands – December 4, 2020 – In their quest of creating safe and effective immunotherapy cancer treatments, LUMICKS and LAVA Therapeutics joined forces. The partnership aims to evaluate the efficacy of various tumor-specific γδ T-cell engagers based on the resulting binding strengths (cell avidity) between T cells and tumors, measured with LUMICKS newly installed z-Movi® Cell Avidity Analyzer.

LAVA Therapeutics develops off-the-shelf bispecific antibodies engineered to simultaneously bind Vγ9Vδ2 T cells and tumor cells to activate tumor-cell killing. The first two γδ T-cell engagers are expected to enter the clinic in 2021.

The company will use the z-Movi® to evaluate select Vγ9Vδ2 T-cell engagers for intercellular binding characteristics in relation to their potential to activate Vγ9Vδ2 T cell-induced tumor killing. Comparison of avidities will provide insights that contribute to the development of future tumor-specific Vγ9Vδ2 T cell engagers.

“We’re thrilled to join forces with LAVA Therapeutics, providing them with an effective tool to better understand characteristics of different γδ T-cell engagers and facilitate selection of top candidates for future clinical trials,” said Zhong Yu, senior global product manager at LUMICKS. “Measurements with the z-Movi® offer an unprecedented approach to study intercellular interactions, which are predictive of T-cell efficacy, and accelerate the development of tumor-specific T-cell engagers as well as other immunotherapeutic candidates.”

About LUMICKS

LUMICKS is a leading life science tools company that develops equipment for dynamic single-molecule and cell avidity analysis, two rapidly emerging areas in biology research and immuno-oncology.  LUMICKS’ tools allow researchers to build the crucial and as yet unfinished bridge between structure and function at both a molecular and a cellular level. This is achieved by applying and measuring forces around biological interactions, enabling the detailed real-time analysis of underlying biological mechanisms. LUMICKS’ C-Trap® Optical Tweezers – Fluorescence & Label-free Microscopy, allows scientists to analyze complex biological processes in real-time. Similarly, the z-Movi® Cell Avidity Analyzer enables the measurement and selection of immune cells based on their real-time interactions with target cells.

LAVA Therapeutics

LAVA Therapeutics is developing a proprietary T-cell engager therapeutics platform for the treatment of hematological and solid cancers. The company’s first-in-class immuno-oncology approach uses bispecific antibodies that activate Vγ9Vδ2 T-cells upon binding to membrane-expressed tumor targets. LAVA was founded in 2016 based on intellectual property originating from the Amsterdam University Medical Center. The company has established a highly experienced research and development team located in Utrecht, the Netherlands and Philadelphia, USA. For more information, please visit www.lavatherapeutics.com.

For more information, contact:

Keely Zipp, VP Corporate Development and Portfolio Strategy

LAVA Therapeutics B.V.

k.zipp@lavatherapeutics.com

Latest company news

Learn as much as you can by reading up on our application notes or marathoning our webinars.

View all
Putting our unused lab equipment to better use

Putting our unused lab equipment to better use

Company news
May 26, 2023
01-01-20

Dynamic Single-molecule workshop at Westlake University

Dynamic Single-molecule workshop at Westlake University

Company news
September 6, 2021
01-01-20

LUMICKS technologies installed all around the world

LUMICKS technologies installed all around the world

Company news
February 23, 2021
01-01-20

LUMICKS featured in LinkedIn Top Start-ups 2020

LUMICKS featured in LinkedIn Top Start-ups 2020

Company news
September 22, 2020
01-01-20